Exploring a Synergistic Approach: Dual GLP-1 Agonist Combined with Degludec Basal Insulin for Early Type 1 Diabetes Treatment and its Impact on Albumin-Insulin Producing Cells Expression.
探索協同療法:雙重 GLP-1 激動劑結合 Degludec 基礎胰島素對早期 1 型糖尿病治療及其對白蛋白-胰島素產生細胞表達的影響。
Adv Pharm Bull 2024-08-29
Fixed-ratio combinations of basal insulin and glucagon-like peptide-1 receptor agonists as a promising strategy for treating diabetes.
固定比例的基礦物質和葡萄糖樣肽-1受體激動劑組合,作為治療糖尿病的有前途策略。
World J Diabetes 2023-04-11
Fixed-ratio Combinations (basal Insulin Plus GLP-1RA) In Type 2 Diabetes. an Analytical Review Of Pivotal Clinical Trials.
第二型糖尿病中固定比例組合(基礎胰島素加 GLP-1RA)的分析性回顧:關鍵臨床試驗。
Rev Diabet Stud 2023-06-01
Glucagon-like peptide-1 receptor agonists as add-on therapy to insulin for type 1 diabetes mellitus.
GLP-1受體激動劑作為額外治療對於第一型糖尿病的胰島素。
Front Pharmacol 2024-01-23
Glucagon-like peptide-1 receptor agonists as a possible intervention to delay the onset of type 1 diabetes: A new horizon.
糖尿病新視野:GLP-1 受體激動劑作為延緩第一型糖尿病發作的可能干預措施。
World J Diabetes 2024-03-12
Comparative Analysis of Orthosteric and Allosteric GLP-1R Agonists' Effects on Insulin Secretion from Healthy, Diabetic, and Recovered INS-1E Pancreatic Beta Cells.
健康、糖尿病和康復的INS-1E胰島β細胞,正交和非正交GLP-1R激動劑對胰島素分泌的比較分析。
Int J Mol Sci 2024-06-27
Liraglutide enhances insulin secretion and prolongs the remission period in adults with newly diagnosed type 1 diabetes (the NewLira study): A randomized, double-blind, placebo-controlled trial.
Liraglutide 增強胰島素分泌並延長新診斷 1 型糖尿病成人的緩解期(NewLira 研究):一項隨機、雙盲、安慰劑對照試驗。
Diabetes Obes Metab 2024-08-28
Assessing the therapeutic and toxicological profile of novel GLP-1 receptor agonists for type 2 diabetes.
評估新型 GLP-1 受體激動劑在 2 型糖尿病中的治療和毒理特徵。
Expert Opin Drug Metab Toxicol 2024-09-13
Mechanistic Pathways and Clinical Implications of GLP-1 Receptor Agonists in Type 1 Diabetes Management.
GLP-1 受體激動劑在 1 型糖尿病管理中的機制途徑及臨床意義。
Int J Mol Sci 2024-09-14